Does Merck & Co., Inc (NYSE:MRK) Have A Strong Drug Portfolio?
Merck & Co., Inc (NYSE:MRK) is the manufacturer of OXYTROL FOR WOMEN. Last week, the company announced that over 20M women who suffer from OSB or overactive bladder can now be benefited with the use of this patch and will be able to gain better control of the condition.
The first of its kind
This patch has to be applied on certain parts of the body every 4 days and has proved to be very effective in treating overactive bladder conditions. This is the one and only OTC option that can be used to treat OAB symptoms such as frequency, urgency or incontinence. These conditions may not seem like severe ones but can affect the emotional and physical condition of women very badly. OAB is of the Top-10 conditions that affect women in America and has an adverse effect on their lives.
They are not able to carry out activities such as work, travel or any other social activities and it also affects their personal life and well-being. Some recent research indicates that this also has a more than $35B annual impact on the economy. This could be either an indirect impact or a direct one. Launching such a product in the market will go a long way in helping a large number of affected women.
In Friday’s trading session, Merck & Co., Inc (NYSE:MRK) stock rose by 0.23%. The opening price of the shares was $47.57 which rose to an intraday high of $47.91 and dropped to a close of $47.79. Approximately 10.51 million shares were traded on Friday and the average volume of shares traded over a 30 day period was $12.97 million. The 52-week low of the shares was $40.02 and the 52-week high was $50.16. The company has a market cap of $139.85 billion.
Merck & Co., Inc (NYSE:MRK) is a global healthcare company. It delivers various health solutions via its vaccines, prescription medicines, consumer-care, biologic therapies, and animal-health products.